CorVel CRVL 深 滬
等待開盤 11-26 09:30:00 美东时间
74.33
+0.450
+0.61%
華盛通- 最 高76.425
- 今 開74.40
- 成交量 20.53万股
- 最 低 74.145
- 昨 收 73.88
- 總市值 38.14亿
- 52周最高 128.61
- 市盈率 靜 40.61
- 換手率 0.00%
- 52周最低 70.47
- 委 比 88.32%
- 總股本 5131.27万
- 歷史最高 128.61
- 量 比 1.31
- 振 幅 3.09%
- 歷史最低 9.36
- 每 手 1
- 風險率 15.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sarah Scott Named to Business Insurance’s “Women to Watch” List for 2025
Sarah Scott, CorVel Corporation's Executive Vice President, has been named to *Business Insurance*'s "Women to Watch" list for 2025. With 26 years at CorVel, Scott has driven innovation, clinical integration, and digital transformation, overseeing product development and advancing technologies like generative AI to enhance patient outcomes and operational efficiency. Michael Combs, CorVel’s President and CEO, praised Scott’s leadership and impact...
11-18 15:44
电话会总结 ｜ CorVel(CRVL)2026财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据CorVel业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年9月季度营收达到2.4亿美元，较2024年9月季度的2.24亿美元增长7%，实现1600万美元的增长。 **盈利能力：** 调整后每股收益为0.54美元，较去年同期的0.45美元增长20%（已调整2024年12月三股拆一股的影响）；净利润从去年同期的2300万美元增长至2800万美元。 **现金状况：** 季度末现金余额为2.07亿美元，公司保持无债务状态；应收账款周转天数(DSO)为40天，较去年同期改善2天。 **股票回购：** 本季度回购1
11-05 12:10
CorVel shares are trading higher after the company reported a year-over-year increase in Q2 financial results.
CorVel shares are trading higher after the company reported a year-over-year in...
11-05 00:11
CorVel Q2 EPS $0.54 Up From $0.45 YoY, Sales $239.643M Up From $224.380M YoY
CorVel (NASDAQ:CRVL) reported quarterly earnings of $0.54 per share. This is a 20 percent increase over earnings of $0.45 per share from the same period last year. The company reported $239.643 million in sales this
11-04 19:13
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
CorVel Announces Revenues and Earnings
CorVel Corporation reported Q3 2025 results with revenues of $240 million, up 7% from the prior year, and earnings per share of $0.54, a 20% increase. The company also saw cash reserves of $207 million and repurchased $12.8 million of stock. Growth initiatives include workforce development through CorVel University and AI enhancements across operations, despite market challenges.
11-04 11:15
CorVel Corporation to Host Live Earnings Release Webcast
CorVel Corporation will host a live webcast on November 4 at 11:30 AM ET to discuss its quarterly earnings and introduce new CFO Brian Nichols. The event, led by CEO Michael Combs, will cover financial performance, strategic initiatives, and include a Q&A session. The webcast will be available via the provided link, with a replay option. Investors may submit questions in advance. CorVel specializes in risk management solutions, using technology t...
10-21 13:13
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Corvus Pharmaceuticals announced interim results from a Phase 1b/2 trial assessing ciforadenant in combination with ipilimumab and nivolumab as a potential first-line therapy for metastatic renal cell cancer (RCC). The trial enrolled 50 patients with advanced RCC, demonstrating the triplet therapy's feasibility, tolerability, and encouraging activity. Key highlights include a 34% deep response rate and a 46% overall response rate, with the median...
10-17 14:00
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to b...
10-06 18:23
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals announced the appointment of David Moore to its Board of Directors. Moore, Executive Vice President at Novo Nordisk, brings 27 years of industry experience in strategy, commercial operations, and business development. His expertise, particularly in successful drug franchises like Ozempic and Wegovy, is expected to strengthen Corvus's ITK inhibitor platform for cancer and immune diseases. Moore expressed excitement about con...
10-02 20:01
